Is Fifty 1 Labs, Inc. (FITY) a Buy, Sell, or Hold?
OTC : FITY
Fifty 1 Labs, Inc.
$0.0006 USD
$0 (0.0%)
- Volume
- 5.04M
- Average Volume
- 14.29M
- Market Capitalization
- $343.13K
- P/E Ratio
- 6.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.00
Company Overview
OTC
Joel Gagnier
Drug Manufacturers - Specialty & Generic
Healthcare
FITY
25
US
USD
Liquidity Metrics
-0.88
0.00
0.00
0.00
0.00
Sales & Valuation
-$
2318.43
-2.46
-24.49
0.00
Profitability
$0.0006
-$359.19K
-37262.84%
-37262.84%
28.76%
-3223.20%
P/E Metrics
6.00
0.06
0.06
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-4297.88
2/9
-$191.54K
$1711.0
$191.68K
-$55149.0
Key Metrics (TTM)
$510.84K
3451.60
-9.26
0.00
28.76%
249.37%
-11.78%
-4.08%
0 days
Company Executives
| Name | Title |
|---|---|
| Joel Gagnier | CEO & Chief Science Officer |
| Alind Gupta | Chief Technology Officer |
| Nima Sakian | Chief Medical Officer |
| Brandon Spikes | President & Director |
| Martin Mills | Chief Growth Officer |
| Richard Robins | Chief Business Development Advisor |
Poll Results
No votes yet today — be the first to share your view!
About Fifty 1 Labs, Inc. (OTC:FITY) Stock
Fifty 1 Labs, Inc. is a Nevada-based holding company that has shifted its focus to biotechnology and telehealth, centering on peptide science for musculoskeletal health, recovery, and performance. The company utilizes AI-driven research and aims to develop a telehealth platform for personalized peptide therapies. Formerly involved in automotive finance, the company is now pursuing growth in the functional medicine and life sciences sectors. ...
Fifty 1 Labs Announces Strategic Evolution into Peptide Biotechnology and Telehealth
2026-07-10 10:00:00
Company outlines dual platform spanning peptide R&D, AI-enabled discovery, and planned U.S. telehealth peptide services VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) (the "Company" or "Fifty 1 Labs") today announced that it is positioning itself as a peptide biotechnology and telehealth company focused on advancing peptide science, musculoskeletal ("MSK") health, recovery, and evidence-driven product innovation. The Company's emerging strategy integrates three complementary areas: peptide research and development, AI-enabled discovery workflows, and a planned U.S.-focused telehealth peptide services platform.
Frequently Asked Questions
-
What is the current Fifty 1 Labs, Inc. (FITY) stock price?
-
Fifty 1 Labs, Inc.(OTC:FITY) stock price is $0.0006 in the last trading session. During the trading session, FITY stock reached the peak price of $0.0048 while $0.0002 was the lowest point it dropped to. The percentage change in FITY stock occurred in the recent session was 0.0% while the dollar amount for the price change in FITY stock was $0.
-
FITY's industry and sector of operation?
-
The OTC listed FITY is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of FITY?
-
Joel Gagnier | CEO & Chief Science Officer
Alind Gupta | Chief Technology Officer
Nima Sakian | Chief Medical Officer
Brandon Spikes | President & Director
Martin Mills | Chief Growth Officer -
How many employees does FITY have?
-
Number of FITY employees currently stands at 25. FITY operates from 751 North Drive, Melbourne, FL 32934, US.
-
Link for FITY official website?
-
Official Website of FITY is: https://fifty1labs.com
-
How do I contact FITY?
-
FITY could be contacted at phone #702 576 9864 and can also be accessed through its website. FITY operates from 751 North Drive, Melbourne, FL 32934, US.
-
How many shares of FITY are traded daily?
-
The average number of FITY shares traded daily for last 3 months was 14.29M.
-
What is the market cap of FITY currently?
-
The market value of FITY currently stands at $343.13K with its latest stock price at $0.0006